The CDMO journey is never just operational, it’s human. In this 7-question Q&A, Philippe Clavel, CEO of Curapath, shares his reflections on the first half of 2025: what we’ve achieved, what we’ve learned, and what it takes to keep growing while staying grounded in purpose and people. This interview goes beyond
VALENCIA, COMUNIDAD VALENCIANA, SPAIN, July 1, 2025 /EINPresswire.com/ — Macro Biologics, Inc. , a US-based company (Carlsbad, Carlifornia) at the intersection of materials science and biotechnology, develops innovative products for healthcare and beyond. Curapath, a CDMO based in Spain, specializes in advanced polymer and lipid synthesis, novel excipients, and nanoparticle formulations. The two
Paterna, May 9, 2025 – Curapath, a global life sciences company specializing in the custom design, development, and manufacturing of advanced drug delivery systems, yesterday welcomed an institutional visit from Felipe Carrasco, Regional Secretary of Industry, Commerce, and Consumer Affairs, and Rafael Escamilla, Director of External Relations at IVACE, at
February 24, 2025, Valencia, Spain – In a significant step towards strengthening its presence in the biotechnology and pharmaceutical sector, CURAPATH has been officially accepted as a member of the Innovation Club of the Valencian Community (CiCV) https://www.clubinnovacioncv.com/. This event took place at the recent General Assembly of the
November 21, 2024, Valencia, Spain, At Curapath, we believe that a fair, inclusive, and diverse workplace is the foundation for innovation and collective well-being. In alignment with this belief, we are proud to announce the official approval and publication of our Gender Equality Plan (GEP), a key milestone that reinforces
Recognized as one of Europe’s Leading Drug Delivery and Manufacturing Companies by Euro Insights Care, Curapath continues to set benchmarks in the field of advanced non-viral drug delivery systems. This accolade underscores the company’s pivotal role in shaping innovative solutions, particularly in polymer and lipid-based therapies. Curapath specializes in the
VALENCIA & ZARAGOZA, SPAIN, 07 OCT 2024. Curapath, a leading innovator in the manufacturing of novel lipid and polymer excipients, nanoparticle formulations and innovative polymer conjugates, and Certest Biotech, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with Lipid Nanoparticles (LNPs) and Active Pharmaceutical
BOSTON and VALENCIA, Feb. 14, 2024 – Curapath, a leader in the development and custom manufacturing of polymer- and lipid-based delivery systems for advanced therapies, has entered into a multiyear Development and Manufacturing Services Agreement with a key customer located in North America. Under this agreement, Curapath will leverage its
Curapath, a developer, manufacturer, and formulator of lipid- and polymer-based nanoparticles used in advanced therapeutic delivery technology, today announced the appointment of Philippe Clavel as Chief Executive Officer. Curapath is a portfolio company of Arcline Investment Management. Philippe has previously held leadership positions in the pharmaceutical and biotechnology industries. Most recently, he
Valencia, Spain and Boston, MA, January 26, 2023 – Curapath, a leader in the design, development, andcustom manufacturing of polyamino-acid- and lipid nanoparticle (LNP) delivery systems for therapeuticsand vaccines, today announced the company has received accreditation as a GMP investigational drugproduct manufacturer from the Spanish Agency for Medicine and Health Products
